Successful treatment of CMV ventriculitis immune reconstitution syndrome [4]

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 6, 2005, Pages 891-892

  Janowicz, Diane M ^a   Johnson, R M ^a   Gupta, S K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BRAIN VENTRICULITIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VENTRICULITIS IMMUNE RECONSTITUTION SYNDROME; FEMALE; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LETTER; MAINTENANCE THERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYNDROME DELINEATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIGENS, CD4; CEREBRAL VENTRICLES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS INFECTIONS; PNEUMONIA, BACTERIAL; ZIDOVUDINE;

EID: 20444404287     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.058438     Document Type: Letter

References (5)

1. Whitley RJ, Jacobson MA, Freidber DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med 1998;158:957-69.
2. Martin D, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Eng J Med 2002;346:1119-26.
3. Anduze-Faris B M, Fillet A, Gozlan J, et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 2000;14:517-24.
4. Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999;37:167-76.
5. Berenguer J, Gonzales J, Pulido F, for the Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis, et al. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin Inf Dis 2002;34:394-7.